Jaguar Health Inc. (NASDAQ: JAGX) will host an investor webcast on Wednesday, August 19, 2026, at 4:30 p.m. Eastern to review its second-quarter 2026 financial results and provide corporate updates. The San Francisco-based company plans to file its Form 10-Q for the quarter ended June 30, 2026, on the same date.

The webcast will be accessible via a registration link provided by the company. A replay of the event will be available on the investor relations section of Jaguar’s website following the broadcast.

Corporate Structure and Focus

Jaguar Health develops novel proprietary prescription drugs sustainably derived from plants for patients with complicated gastrointestinal (GI) disease states. The company operates through several family entities:

• Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of crofelemer powder for oral solution. This treatment targets rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.
• Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp., emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI). It is focused on developing novel prescription medicines derived from plants for mental health indications.

Forward-Looking Statements

The press release contains forward-looking statements regarding the expectation that Jaguar will file its Form 10-Q on August 19, 2026, and hold the investor webcast on the same day. These statements are based on current expectations and projections about future events. They speak only as of the date of the release and are subject to risks, uncertainties, and assumptions, some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained in the release.

Jaguar Health, Inc. announced that its family company Napo Pharmaceuticals presented new data at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Meeting in Lille, France. The presentations highlighted the efficacy of oral liquid crofelemer as an adjunctive therapy for pediatric intestinal failure (IF) patients. The results demonstrated substantial reductions in parenteral support (PS) requirements, a critical metric for patients dependent on lifelong total parenteral nutrition.

The data presented showed that in one patient with microvillus inclusion disease (MVID), weekly PS requirements normalized to body weight were reduced by up to 48% following more than 12 months of liquid oral high-dose crofelemer therapy. Additionally, in two pediatric patients with short bowel syndrome with intestinal failure (SBS-IF), weekly PS requirements normalized to body weight were reduced by up to 40% over the same treatment period. The therapy was well tolerated with no significant clinical or laboratory abnormalities reported throughout the ongoing treatment period.

Jaguar Health remains focused on its global development program for crofelemer. The company is targeting Breakthrough Therapy designation for crofelemer for the indication of MVID, with a planned filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in mid-2027. The company stated that its intestinal failure program is expected to continue to provide clinical milestones and is the subject of business development discussions aimed at securing non-dilutive funds from potential licensee partners.

Clinical Trial Results Summary

Separately, Jaguar Health recently exercised its right to convert its Series O Convertible Preferred Stock into voting common stock. The conversion automatically took effect at 12:00 pm Eastern Time on June 25, 2026. Each share of Preferred Stock converted into 3.209 shares of Common Stock. Holders who would have received fractional shares received cash based on the fair value of the fractional interest, calculated at the closing price of $2.68 per share on June 24, 2026. The Preferred Stock was originally issued as a one-time special stock dividend to holders of Jaguar Common Stock and certain outstanding warrants as of the record date on March 2, 2026.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas. Its family companies, Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A., focus on the development and commercialization of crofelemer.